Na-akwado Peptide IND maka nyocha ngwa ngwa FDA: Ndepụta nyocha CMC

Na-akwado Peptide IND maka nyocha ngwa ngwa FDA: Ndepụta nyocha CMC

Na-akwado Peptide IND maka nyocha ngwa ngwa FDA: Ndepụta nyocha CMC

Ndị FDA Ọgwụ ọhụrụ nyocha ngwa ngwa (IND) Mmemme pilot na-enye ndị mmepe biopharmaceutical ohere a na-enwetụbeghị ụdị ya iji mee ka usoro ọgwụgwọ oge mbụ maka ọgwụgwọ ọgwụgwọ dị elu.. Agbanyeghị, maka peptides sịntetik — ngwakọta ndị na-enwe ohere nchịkwa pụrụ iche n'etiti obere ụmụ irighiri ihe na ihe ndị dị mgbagwoju anya - usoro iheomume ngwa ngwa na-eweta kemịkalụ dị egwu., Imepụta, na njikwa (CMC) ịma aka.

Na-akwado Peptide IND maka nyocha ngwa ngwa FDA: Ndepụta nyocha CMC

Ọ bụ ezie na ntuziaka FDA na-enye mgbanwe mgbanwe CMC dabara adaba maka oge mbụ n'ime mmadụ (FIH) Usoro 1 ọnwụnwa, Ụzọ nleba anya ngwa ngwa adịghị ewetu nchekwa iwu ma ọ bụ ogwe njirimara dị n'okpuru Ntuziaka CMC nke mbụ FDA. Kama, Ndị nyocha FDA CDER na-enyocha dossier peptide IND maka njirimara orthogonal siri ike, nkọwapụta adịghị ọcha zuru oke, nkwụsi ike n'okpuru usoro ọgwụgwọ echere, yana inye GMP reproducible.

Iji nyere biopharma R&D otu, ndu oru ngo, na ndị isi CMC na-agagharị mpio ntinye ngwa ngwa a na-enweghị mkpalite arịrịọ ozi (IRs) ma ọ bụ ụlọ ọgwụ ejide, Ndepụta atụmatụ nka na-akụda ogidi CMC ise dị mkpa achọrọ maka ngwungwu peptide IND dị njikere..

Na-akwado Peptide IND maka nyocha ngwa ngwa FDA: Ndepụta nyocha CMC

Ọgwụ 1: njirimara & Nkwenye ịdị ọcha site na nyocha Orthogonal

Ọnyà a na-ahụkarị na ntinye akwụkwọ peptide IND na-adabere n'otu usoro nyocha - nke na-agbanwe agbanwe-Phase High-Performance Liquid Chromatography (RP-HPLC) na nchọpụta UV-iji gosipụta ịdị ọcha na njirimara ọgwụ.

Ntugharị igodo: Ma FDA CDER na EMA regulatory frameworks kwuputara nke ọma na otu nyocha RP-HPLC ezughi oke iji gosi njirimara peptide sịntetị na ịdị ọcha.. Ntinye akwụkwọ IND ga-egosipụta nkwenye nhazi site na iji opekata mpe abụọ nwere onwe, usoro nyocha nke physicochemically orthogonal.

Na-akwado Peptide IND maka nyocha ngwa ngwa FDA: Ndepụta nyocha CMC

Kedu ihe kpatara Nnwale Otu RP-HPLC ji ada nyocha usoro nhazi

Ọ bụ ezie na RP-HPLC kacha mma na ikewa adịghị ọcha peptidic metụtara dabere na mmekọrịta hydrophobic., ọ nweghị ike idozi ụdị isobaric na-ejikọta ọnụ, usoro iwu isomers, ma ọ bụ usoro ihichapụ nke na-ekekọrịta oge njigide yiri ya. Ndị nyocha na-atụ anya matriks nyocha ọtụtụ akụkụ nke na-enyocha usoro nke mbụ, ezigbo uka, ụgwọ net, na quantitative stoichiometry.

Ịmepụta Panel Orthogonal dị njikere nyocha

izute atụmanya iwu maka ule peptide orthogonal, Nkọwapụta ntọhapụ IND nke mmalite kwesịrị ijikọ usoro mmekọ ndị a:

Na-akwado Peptide IND maka nyocha ngwa ngwa FDA: Ndepụta nyocha CMC
  1. Mkpebi Hydrophobic (RP-HPLC / UHPLC): Na-akọwapụta ịdị ọcha mpaghara-pasent, na-emepụta profaịlụ chromatographic ntọala, ma na-esetịpụ ọnụ ụzọ adịghị ọcha n'otu n'otu na mkpokọta.
  2. Mass ziri ezi & Nyocha usoro (ESI-LC-MS/MS ma ọ bụ HRMS): Na-akwado ịdị arọ molekụla monoisotopic ziri ezi ma na-eji nkewa na-ebute nkukota (CID) iberibe ion (b na y usoro) iji nyochaa usoro amino acid bụ isi.
  3. Analysis Variant Charge Electrophoretic (Capillary Electrophoresis / CE): Na-edozi ngwaahịa mmebi iwu dabere na ụgwọ, dị ka deamidation ma ọ bụ C-terminal mgbanwe, nke ahụ nwere ike jikọta na RP-HPLC.
  4. Ọnụ ọgụgụ nke Stoichiometry (Amino Acid Analysis / AAA): Na-akwado oke amino acid ziri ezi ma nye onwe ya, nha ziri ezi nke ọdịnaya peptide net (dị iche na mkpokọta ntụ ntụ).

Mgbe ị na-ewepụta nkọwa ntọhapụ n'oge, ndị nkwado kwesịrị itinye ndị ọkachamara orthogonal analytical QC na ọrụ njirimara iji kwado nkọwapụta usoro tupu imepụta ihe nnwale ụlọ ọgwụ.


Ọgwụ 2: Nkọwapụta adịghị ọcha dị elu & Njirimara nhazi

N'okpuru nlebanya IND emelitere, ndị na-achịkwa chọrọ nghọta doro anya gbasara profaịlụ adịghị ọcha nke ọgwụ. peptides sịntetik emepụtara site na Synthesis Peptide siri ike (SPSS) na-ebu usoro na ngwaahịa adịghị ọcha nke a ga-achọpụtarịrị, ọnụọgụgụ, na ihe ize ndụ-nyochaa maka ike immunogenicity.

Na-akwado Peptide IND maka nyocha ngwa ngwa FDA: Ndepụta nyocha CMC

SYNTETIC PEPTIDE adịghị ọcha profaịlụ adịghị ọcha metụtara ngwaahịa | Ihe adịghị ọcha metụtara usoro • ihichapụ / Usoro nkwụsịtụ | • Residual Coupling Reagents (EDC, HOBt) • Deamidation (Asn → Asp/isoAsp) | • Ihe mgbaze fọdụrụnụ (DMF, ACN, Piperidine) • Epimerization (D/L diastereomers)| • Mgbochi ndị fọdụrụ (TFA vs Acetate) • Oxidation (zutere, Tp, Cys) | • Ọla dị arọ & Chọpụta Reagent

Na-edozi nhichapụ & Usoro nkwụsịtụ

Njikọ amino acid ezughị ezu n'oge SPPS na-emepụta usoro nhichapụ ($n-1, n-2$) na peptides ewepụghị. Ekwesịrị iji maapụ iberibe LC-MS/MS dị elu rụọ ọrụ iji wepụta ihe ndị na-efu efu wee hụ na ọ nweghị otu adịghị ọcha nhichapụ amaghi ama gafere oke ntozu ICH. (na-emekarị >0.10% ma ọ bụ >0.15%, dabere na dose kwa ụbọchị).

Na-akwado Peptide IND maka nyocha ngwa ngwa FDA: Ndepụta nyocha CMC

Nsochi Deamidation & Ihe na-emebi oxidation

  • Deamidation: Asparagine (Asn) ihe fọdụrụ ngwa ngwa na-enweta nkụda mmụọ iji guzobe etiti imide cyclic, na-enye ngwakọta nke aspartate (Asp) na Isoaspartate (isoAsp). N'ihi na isoAsp na-agbanwe ọkpụkpụ azụ peptide, CE ma ọ bụ chromatography mgbanwe mgbanwe ion dị elu ga-akwadorịrị iji soro ụzọ mmebi a..
  • Oxidation: Methionine (zutere), Tryptophan (Tp), na cysteine (Cys) Residues bụ ngwangwa oxidation n'oge cleavage na ọcha. Ụzọ RP-HPLC nke na-egosi nkwụsi ike ga-edozirịrị sulfoxide na ụdị formyl sitere na ọnụ ọgụgụ kasị elu nke nne na nna API..

Na-egosipụta Epimerization & Diastereomers na-agba ọsọ

Ịgba ọsọ na ụlọ ọrụ alfa-carbon n'oge ịgbalite C-terminal na-emepụta D-amino acid diastereomers. (epimers). N'ihi na epimers nwere otu ihe ọ̀tụ̀tụ̀ molekụla ma na-ejikọta ya na peptide L-target na kọlụm RP-HPLC ọkọlọtọ., chromatography nke chiral, enzymatic mgbaze, ma ọ bụ NMR spectroscopy ezubere iche ga-emerịrị iji wepụta ịdị ọcha stereochemical.

Mgbanwe Mgbanwe TFA fọdụrụnụ & Njikwa ọdịnaya nnu

Peptides sachara na trifluoroacetic acid (TFA) Usoro mkpanaaka na-ejigide TFA dị ka mgbochi. N'ihi na TFA na-egosiputa nsi cellular ma nwee ike mebie nkwụsi ike izizi, IND-ọkwa sịntetik peptides chọrọ mgbanwe counterion ka acetate ma ọ bụ chloride nnu.

Na-akwado Peptide IND maka nyocha ngwa ngwa FDA: Ndepụta nyocha CMC

Maka ndụmọdụ: Na-akọwapụta ion Chromatography mgbe niile (IC) ma ọ bụ ^{19}F-NMR iji gosi na ọkwa TFA fọdụrụnụ ka dị n'okpuru 1.0% (w/w) na ikpeazụ ọgwụ umi otutu.

Maka usoro mgbagwoju anya na akụkụ hydrophobic ma ọ bụ mkpokọta na-adịkarị mfe, iso ndị ọkachamara nwere nkà na-akpakọrịta omenala peptide njikọ na ọcha na-eme ka ntughari mgbochi dị irè na ikewapụ mkpụrụ dị elu.

Na-akwado Peptide IND maka nyocha ngwa ngwa FDA: Ndepụta nyocha CMC

Ọgwụ 3: Nkwụsi ike nhazi & Ndakọrịta akpa-mmechi

Ịkwado ntinye akwụkwọ IND agbakwunyere, ndị nkwado ga-egosipụta na ngwaahịa ọgwụ nyocha ka kwụsiri ike, soluble, ma na-arụsi ọrụ ike n'ụzọ ndụ n'ime oge nnwale ụlọ ọgwụ a tụrụ aro.

⚠️ Ịdọ aka ná ntị: Ihe na-akpatakarị arịrịọ arịrịọ FDA bụ inyefe data nkwụsi ike nke ewepụtara naanị site na ntụ ntụ ntụ ọgwụ, karịa usoro ọgwụgwọ a chọrọ (eg., ngwọta mmiri echekwabara na vial/syringe ikpeazụ).

Na-akwado Peptide IND maka nyocha ngwa ngwa FDA: Ndepụta nyocha CMC

Nnwale na-egosi nkwụsi ike & Nnwale nrụgide

Ndị na-enyocha FDA na-atụ anya nkwụsi ike data emepụtara n'okpuru ngwakọta nke ọnọdụ nchekwa:

  • Nchekwa ogologo oge: 2Celsius C - 8 Celsius ma ọ bụ -20 Celsius (na-ekpuchi ogologo oge protocol ụlọ ọgwụ a tụrụ anya ya).
  • Ọnọdụ agbakwunyere: 25Celsius C / 60% RH maka kinetics mmebi iwu.
  • Mmebi amanye (Nnwale nrụgide): Ikpughe ụma na acid, isi, peroxide oxidation, ikpo ọkụ, na photolysis. Ọmụmụ ihe ndị a kwadoro na nyocha ntọhapụ bụ nkwụsi ike n'ezie na-egosi ma nwee ike ịchọpụta ihe ndị na-emebi emebi.

Solubility, Mkpokọta, yana Mmekọrịta-mmechi-akpa

Peptides dị n'ụdị mmiri mmiri na-enwe ike ịmekọrịta onwe ya na nhazi fibril. Ngwungwu kwụsie ike ga-enyocharịrị:

  • Solubility & Profaịlụ pH: Na-akwado mgbasa zuru oke n'ofe pH physiological ebumnuche na-enweghị ọdịda mmiri.
  • Particulates na-ahụ anya & Mkpokọta: Iji chromatography nha-wepu (SEC) ma ọ bụ Dynamic Light Scattering (DLS) iji soro oligomers soluble.
  • Ndakọrịta akpa-mmechi: Na-enyocha nnabata peptide na vials iko, ihe nkwụsị nke elastomers, ma ọ bụ tubing nnyefe nke eriri afọ.

Ọgwụ 4: Ntinye GMP Batch nwere ike imegharị & Njikwa ime ụlọ adịghị ọcha

Mmemme nleba anya ngwa ngwa na-etinye aka siri ike na ntụkwasị obi nke agbụ ọkọnọ na nrụpụta nrụpụta. Ndị na-enyocha FDA na-atụ anya ihe akaebe na usoro a na-eji maka batches na-abụghị nke ụlọ ọgwụ nwere ike ịmaliteghachi mgbe niile n'okpuru Ezi Omume nrụpụta. (GMP) ụkpụrụ maka akụrụngwa nnwale mmadụ.

Na-egosi nkwekọ n'ọtụtụ-na-Lot

Dossier IND emelitere kwesịrị iwepụta data nyocha batch ma ọ dịkarịa ala nza atọ n'usoro (eg., abụọ na-abụghị ụlọ ọgwụ / injinia nza na otu GMP nza). Igodo ntụnyere gụnyere:

  • Mpaghara-pasent ịdị ọcha agbanwe agbanwe (± 1.0%).
  • Dakọtara profaịlụ mkpịsị aka adịghị ọcha n'ofe nza.
  • Oke mgbochi n'ụdị na ọdịnaya mmiri (Nkọwa nke Karl Fischer).

Klas 100 Njikwa ime ụlọ ọcha: Ibu ibu, Ịgba nwa, na endotoxin

Maka ọgwụgwọ peptide parenteral, njikwa mmepụta ihe na-adịghị mma bụ enweghị mkparịta ụka. Nrụpụta ga-emerịrị n'ime nkwenye Klas 100 (ISO 5) gburugburu ime ụlọ na-adịghị ọcha iji hụ na nrube isi na oke microbiological:

  • Endotoxin nke nje bacteria: <0.2 EU/mg (ma ọ bụ nke ọma n'okpuru mmadụ dose dabeere n'ọnụ ụzọ kwa USP <85> Nnwale Endotoxins nke nje).
  • Nnwale ịmụ nwa: Dabara na USP <71> Nnwale ịmụ nwa Usoro nzacha akpụkpọ ahụ.
  • Njikwa bioburden: Nlekọta bioburden siri ike n'oge njikọ, filtration, na lyophilization kwa USP <1229> nduzi.

Ọgwụ 5: Nkwenye dabere n'ihe egwu maka nkwalite usoro nhọpụta gachaa

Na mmepe ngwa ngwa, Nhazi na usoro nchacha na-apụtakarị n'etiti nhọrọ ndu mbụ na nrịgo GMP. Ndị nkwado nwere ike ịgafe site na SPPS akwụkwọ ntuziaka gaa na njikọ mgbaba akpaghị aka, bulie cleavage cocktails, ma ọ bụ ọnụ ọgụgụ kọlụm chromatography site na gram ruo kilogram.

Nhọrọ Onye Nduzi (mg/g) ► Nkwalite usoro ► Nweta GMP Clinical (g/kg)

Profaịlụ adịghị ọcha mbụ ntụnyere Profaịlụ adịghị ọcha ► Ntụnyere dabere n'ihe ize ndụ ◄ (ICH Q5E Framework)

Ịmepụta ụkpụrụ ntụnyere dabere na ihe ize ndụ (I Q5E)

Mgbe n'ichepụta usoro mmezi eme mgbe nhọrọ, ndị nkwado ga-edozi ntule ihe egwu ahaziri ahazi dabara na ya Ụkpụrụ ntụnyere ICH Q5E. Ebumnuche bụ isi bụ igosipụta na mgbanwe usoro anaghị emetụta nchekwa ngwaahịa, ike, ma ọ bụ ịdị ọcha.

Ịkwado Mgbanwe Usoro Nhọrọ Mkpebi

  1. Ntụnyere nyocha n'akụkụ n'akụkụ: Gbaa nza tupu mgbanwe na mgbanwe mgbanwe n'otu panel nyocha nke orthogonal kwadoro.
  2. Mkpokọta profaịlụ adịghị ọcha: Kwenye na ọnweghị adịghị ọcha ọhụrụ amaghi ama pụtara n'elu 0.10% na ọkwa adịghị ọcha dị adị ka hà nhata ma ọ bụ dị ala karịa nza ụlọ ọgwụ tupu agbanwee.
  3. Akwụkwọ ziri ezi dabere n'ihe ize ndụ: Ọ bụrụ na obere mgbanwe n'ime mbelata ma ọ bụ ụdị nnu na-eme, nye nkọwa doro anya na-akwado toxicology na-akọwa ihe kpatara mgbanwe ahụ ji eweta ihe egwu ọzọ na-enweghị atụ na isiokwu mmadụ.

Ndị nkwado na-achọ ịhazi ntugharị ọnụ ọgụgụ dị elu nwere ike iji ndị nwere ahụmahụ peptide CRO usoro mmepe na mmụba otu iji guzobe ụkpụrụ ntụnyere siri ike tupu nrubeisi IND.


Ndepụta Njikere Tactical maka Mbubata Peptide IND

Jiri matriks nchịkọta a iji nyochaa dossier CMC gị tupu ịnyefe arịrịọ gị isonye na mmemme pilot FDA Expedited IND.:

Ogidi CMC Ngwa nka achọrọ Usoro nyocha nke izizi Usoro nnabata ebumnuche / Atụmanya nchịkwa Ọnọdụ
Ọgwụ 1: njirimara & Ịdị ọcha Usoro nke izizi & Mass ESI-LC-MS/MS ma ọ bụ HRMS Monoisotopic uka dakọtara na usoro iwu; b/y iberibe ion kwadoro usoro [ ]
Ọcha Orthogonal RP-HPLC + CE Mpaghara-pasent ịdị ọcha ≥ 95.0-98.0%; nkewa ụgwọ mmekọ [ ]
Ọdịnaya Peptide Amino Acid Analysis (AAA) Quantitative stoichiometry; ọdịnaya peptide net ziri ezi [ ]
Ọgwụ 2: Nkọwapụta adịghị ọcha ihichapụ / Mbipu UHPLC-HRMS/MS Ihe adịghị ọcha nke onwe onye amaghi ama < 0.10%; ọrụ nhazi zuru oke [ ]
Deamidation & Oxidation CE / RP-HPLC A na-agụta ihe ndị rụrụ arụ; kwụsie ike na-egosi nkewa kwadoro [ ]
Epimers Stereochemical Ụlọ ọrụ LC / NMR / CD D-amino acid diastereomers mara ma na-achịkwa ya [ ]
Mkpesa / TFA Ion Chromatography / ^{19}F-NMR Mgbanwe mgbanwe; ihe fọdụrụ TFA nke ọma < 1.0% (w/w) [ ]
Ọgwụ 3: Nkwụsi ike Nkwụsi ike nhazi RP-HPLC / SEC Nnwale na-egosi nkwụsi ike kwadoro n'okpuru ezigbo oge yana 25°C/60% RH [ ]
Mmebi amanye Acid/Base/Okpomọkụ/Ìhè/Ox. Atụle nha nha oke; ụzọ rụrụ arụ mapụtara [ ]
Mkpokọta & Na-akọwapụta SEC / DLS / USP <788> A na-achịkwa oligomer soluble; obere irighiri ihe a na-ahụ anya n'ime oke [ ]
Ọgwụ 4: GMP & Ịgba nwa Mmegharị ogbe 3 Ọtụtụ n'usoro Ọdịiche dị ọcha nke ọtụtụ-na-ọtụtụ ≤ 1.0%; profaịlụ chromatographic dakọtara [ ]
Njikwa ime ụlọ ọcha Klas 100 Ime ụlọ ọcha Endotoxin < 0.2 EU/mg; USP <71> akpali mmasị; a na-enyocha bioburden [ ]
Ọgwụ 5: Usoro ziri ezi Ọmụmụ Ntụnyere Nyocha ICH Q5E Tupu- vs mgbanwe mgbanwe nza tụnyere; adịghị ọhụrụ adịghị ọcha > 0.10% [ ]

Mmekọrịta maka nleba anya-njikere Peptide IND

Ịnyagharị FDA's Expedit IND Pilot chọrọ ihe karịrị ọsọ-ọ na-achọ njirimara nyocha na-adịghị emebi emebi., njirimara adịghị ọcha siri ike, na mmebe mmepụta ihe na-enweghị ntụpọ.

Na MOL mgbanwe, anyị na-akwado ndị mmepe biopharmaceutical, CROs, na ndị na-eme nchọpụta agụmakwụkwọ n'ịchịkọta ọdịiche dị n'etiti nhọrọ ndị na-eme ntuli aka na ntinye ule ụlọ ọgwụ. Na-arụ ọrụ n'ime Klas 100 gburugburu ime ụlọ dị ọcha nke ultra-sterile, Ngwakọta peptide anyị agbakwunyere na-ebuga:

  • Ngwakọta peptide omenala gbagoro site na milligrams ruo kilogram.
  • gafere 300 mgbanwe otu ọrụ, biotinylation, fluorescent labeling, na mgbagwoju anya bio-conjugation.
  • Nkwakọ ngwaahịa QC orthogonal siri ike, gụnyere ule ịdị ọcha HPLC, nkwenye usoro LC-MS/MS dị elu, ntụgharị counterion, na akwụkwọ nyocha zuru oke (CoA) akwụkwọ.

Ma ị na-ebuli usoro peptide dị mgbagwoju anya ma ọ bụ na-akwado dossier CMC gị maka ntinye FDA ngwa ngwa., nyochaa ka nka nka nka nwere ike isi mebie uzo nhazi gi. Kpọtụrụ ndị otu mgbanwe MOL taa ịrịọ maka nyocha teknụzụ ma ọ bụ kparịta njikọ peptide ọkwa ụlọ ọgwụ omenala.


Banyere Onye dere ya & Nyocha sayensị

Odee: MOL na-agbanwe Sayensị Peptide & Nka na ụzụ Editorial Board
Onye nyocha sayensị: Dr. Elena Vance, Ph.D. na Organic Chemistry
Onye isi nchịkwa nke CMC & Mmesi obi ike nke Peptide, MOL mgbanwe

Dr. Vance na-akwụsị 15 afọ nke ahụmahụ mmepụta ihe na ọgwụgwọ peptide njikọ, nkwado usoro nyocha (orthogonal LC-MS/MS, CE), yana nkwadebe dossier CMC maka ntinye nyocha FDA na EMA. MOL Changes Technical Editorial Board nwere ndị na-ahụ maka kemịkalụ sịntetik nke ọkwa doctorate, ndị ọkà mmụta sayensị nyocha, na ndị ọkachamara n'usoro iwu raara onwe ha nye ịkwalite mmepe ọgwụ peptide ọgwụgwọ na ụkpụrụ ịdị mma.

admin Avatar

Jinling Liu

Usoro R&D na teknụzụ nrụpụta Ọkachamara isi: Nkwalite usoro, onwu onwu, mkpụrụ mma, Nkwekọrịta mmepụta GMP.

Profaịlụ: Jinling Liu bụ ọkachamara na ntụgharị usoro ọgwụ peptide sitere na ọnụ ọgụgụ ụlọ nyocha (milligram ọkwa) na mmepụta nke ọnụ ọgụgụ azụmahịa (ọkwa kilogram). O kpebisiri ike ibelata ọnụ ahịa mmepụta peptide nke ọma yana ibelata mmetọ gburugburu ebe obibi site na ịkwalite ọnọdụ mkpochapụ., imeziwanye oke nke reagents condensation, na iwebata teknụzụ njikọ njikọ na-aga n'ihu. Ọ duruwo njikarịcha ọtụtụ ọrụ peptide, na-enweta ọnụ ala dị ala nke ọma, mmepụta oke dị elu dị elu na 100-kilogram.

Achọpụtara eziokwu & Ntuziaka ndezi
Nyochaa ya bụ: Ndị ọkachamara Okwu
Kesaa akụkọ a
Ụlọ Chọọ WhatsApp Ọrụ Ngwaahịa